La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Longeveron Dividendo

Dividendo criteri di controllo 0/6

Longeveron non ha registrato alcun pagamento di dividendi.

Informazioni chiave

n/a

Rendimento del dividendo

n/a

Rapporto di remunerazione

Rendimento medio del settore	2.0%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	n/a
Utile per azione	-US$1.94
Previsione del rendimento del dividendo a 3 anni	n/a

Aggiornamenti recenti sui dividendi

Nessun aggiornamento

Recent updates

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Jul 07

Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market

May 06

Companies Like Longeveron (NASDAQ:LGVN) Are In A Position To Invest In Growth

Apr 03

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: Dati insufficienti per determinare se i dividendi per azione di LGVN siano rimasti stabili in passato.

Dividendo in crescita: Dati insufficienti per determinare se i pagamenti dei dividendi di LGVN siano aumentati.

Rendimento dei dividendi rispetto al mercato

Longeveron Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di LGVN rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (LGVN)	n/a
Fondo del 25% del mercato (US)	1.4%
Top 25% del mercato (US)	4.5%
Media del settore (Biotechs)	2.0%
Previsione dell'analista in 3 anni (LGVN)	n/a

Dividendo notevole: Impossibile valutare il rendimento dei dividendi di LGVN rispetto al 25% inferiore dei pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Dividendo elevato: Impossibile valutare il rendimento dei dividendi di LGVN rispetto al 25% dei maggiori pagatori di dividendi, poiché la società non ha segnalato alcun pagamento recente.

Distribuzione degli utili agli azionisti

Copertura degli utili: Dati insufficienti per calcolare il payout ratio di LGVN per determinare se i suoi pagamenti di dividendi sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Impossibile calcolare la sostenibilità dei dividendi poiché LGVN non ha segnalato alcun pagamento.

Longeveron Dividendo

Dividendo criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Recent updates

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Longeveron Inc. to Report Q2, 2024 Results on Aug 14, 2024

Consensus revenue estimates increase by 21%

Price target decreased by 10% to US$11.32

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer’s Disease at the Alzheimer’s Association International Conference® (AAIC)

Consensus EPS estimates upgraded to US$3.42 loss

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $9.000005 million.

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron® Announces U.S. FDA Grants Fast Track Designation for Lomecel-B™ for the Treatment of Mild Alzheimer’s Disease

Longeveron Inc. Announces U.S. FDA Grants Lomecel-B Regenerative Medicine Advanced Therapy (RMAT) Designation for the Treatment of Mild Alzheimer's Disease

Longeveron Inc. Elects Neha Motwani to Its Board of Directors

Longeveron Inc. Appoints Roger Hajjar to Board of Directors

Price target decreased by 12% to US$12.30

Consensus EPS estimates upgraded to US$3.91 loss

Longeveron Inc., Annual General Meeting, Jul 02, 2024

Consensus revenue estimates increase by 931%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Longeveron Inc. Announces Board Changes

Longeveron Inc. to Report Q1, 2024 Results on May 14, 2024

Consensus EPS estimates upgraded to US$5.85 loss

Price target decreased by 48% to US$37.50

New major risk - Share price stability

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $5.248428 million.

New major risk - Shareholder dilution

New major risk - Market cap size

Longeveron Announces 1-For-10 Reverse Stock Split to Regain Compliance

Longeveron Inc. has filed a Follow-on Equity Offering.

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Longeveron Receives a Notice from the Listing Qualifications Department of the Nasdaq Stock Market Regarding Minimum Bid Price Requirement

Full year 2023 earnings: EPS misses analyst expectations

Longeveron Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Longeveron Inc. has completed a Follow-on Equity Offering in the amount of $2.365 million.

Longeveron Inc. has filed a Follow-on Equity Offering in the amount of $2.195588 million.

Longeveron Announces Additional Positive Clinical Data and Imaging Biomarker Results from the Clear Mind Phase 2A Trial of Lomecel-B™ in the Treatment of Mild Alzheimer’S Disease

Long-Term Survival Data from Longeveron’s Elpis 1 Trial Presented At the 2023 Scientific Sessions of the American Heart Association

Longeveron Inc. to Report Q3, 2023 Results on Nov 10, 2023

Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from Clear MIND Phase 2a Clinical Trial of Lomecel-B™? for the Treatment of Mild Alzheimer's

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%

Longeveron Inc. Announces Positive Top-Line Results for Lomecel-B in Its Clear Mind Phase 2A Clinical Trial in the Treatment of Mild Alzheimer’s Disease

Director exercised options to buy US$70k worth of stock.

New major risk - Revenue size

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces Achievement of Surpassing 50% Enrollment Threshold in Phase 2 ELPIS II Study of Lomecel-B™ in Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q2, 2023 Results on Aug 11, 2023

Longeveron Inc. Announces the Appointment of Lisa Locklear as Chief Financial Officer, Effective July 31, 2023

Longeveron Inc. Appoints Nataliya Agafonova M.D. as Chief Medical Officer

High number of new directors

Longeveron Inc. Approves Bord Appointments

Longeveron Inc. Announces Resignation of James Clavijo as CFO

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Longeveron Inc Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome

Longeveron Inc. to Report Q1, 2023 Results on May 12, 2023

Full year 2022 earnings released: US$0.90 loss per share (vs US$0.90 loss in FY 2021)

Price target decreased to US$15.50

Longeveron Provides Corporate Update

Consensus forecasts updated

Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

High number of new directors

Longeveron Inc. Announces Completion of Enrollment in Phase 2a Trial of Lomecel-B™ for the Treatment of Alzheimer’S Disease

Longeveron Inc. to Report Q3, 2022 Results on Nov 14, 2022

Longeveron Inc.: A New Approach To Treat Alzheimer's

U.S. Food and Drug Administration (FDA) Grants Fast Track Designation for Longeveron's Lomecel-B(TM) Product for Treatment of Hypoplastic Left Heart Syndrome (HLHS) in Infants

Longeveron spikes after FDA’s Fast Track Designation for lead candidate

Consensus revenue estimates fall by 12%

Second quarter 2022 earnings released: US$0.27 loss per share (vs US$0.26 loss in 2Q 2021)

Longeveron Inc. to Report Q2, 2022 Results on Aug 12, 2022

Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?

Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference

Director notifies of intention to sell stock

CFO & Treasurer recently sold US$305k worth of stock

Director recently sold US$153k worth of stock

First quarter 2022 earnings: EPS and revenues exceed analyst expectations